185 related articles for article (PubMed ID: 25236997)
1. Pharmaceutical portfolio management: global disease burden and corporate performance metrics.
Daems R; Maes E; Mehra M; Carroll B; Thomas A
Value Health; 2014 Sep; 17(6):732-8. PubMed ID: 25236997
[TBL] [Abstract][Full Text] [Related]
2. Investigating investment in biopharmaceutical R&D.
Carter PH; Berndt ER; DiMasi JA; Trusheim M
Nat Rev Drug Discov; 2016 Oct; 15(10):673-4. PubMed ID: 27616295
[TBL] [Abstract][Full Text] [Related]
3. Regional patterns of disability-free life expectancy and disability-adjusted life expectancy: global Burden of Disease Study.
Murray CJ; Lopez AD
Lancet; 1997 May; 349(9062):1347-52. PubMed ID: 9149696
[TBL] [Abstract][Full Text] [Related]
4. Disease burden metrics and the innovations of leading pharmaceutical companies: a global and regional comparative study.
Jung YL; Hwang J; Yoo HS
Global Health; 2020 Sep; 16(1):80. PubMed ID: 32912258
[TBL] [Abstract][Full Text] [Related]
5. Medications development for substance-use disorders: contextual influences (dis)incentivizing pharmaceutical-industry positioning.
Janero DR
Expert Opin Drug Discov; 2014 Nov; 9(11):1265-79. PubMed ID: 25162124
[TBL] [Abstract][Full Text] [Related]
6. Research Investments in Global Health: A Systematic Analysis of UK Infectious Disease Research Funding and Global Health Metrics, 1997-2013.
Head MG; Fitchett JR; Nageshwaran V; Kumari N; Hayward A; Atun R
EBioMedicine; 2016 Jan; 3():180-190. PubMed ID: 26870829
[TBL] [Abstract][Full Text] [Related]
7. R&D efficiency of leading pharmaceutical companies - A 20-year analysis.
Schuhmacher A; Wilisch L; Kuss M; Kandelbauer A; Hinder M; Gassmann O
Drug Discov Today; 2021 Aug; 26(8):1784-1789. PubMed ID: 34022459
[TBL] [Abstract][Full Text] [Related]
8. Just how good an investment is the biopharmaceutical sector?
Thakor RT; Anaya N; Zhang Y; Vilanilam C; Siah KW; Wong CH; Lo AW
Nat Biotechnol; 2017 Dec; 35(12):1149-1157. PubMed ID: 29220034
[TBL] [Abstract][Full Text] [Related]
9. Finally, a way to put your Internet portfolio in order.
Tjan AK
Harv Bus Rev; 2001 Feb; 79(2):76-85, 156. PubMed ID: 11213700
[TBL] [Abstract][Full Text] [Related]
10. Public funding and private investment for R&D: a survey in China's pharmaceutical industry.
Qiu L; Chen ZY; Lu DY; Hu H; Wang YT
Health Res Policy Syst; 2014 Jun; 12():27. PubMed ID: 24925505
[TBL] [Abstract][Full Text] [Related]
11. The perfect mix for your portfolio.
Simons J
Fortune; 2003 Dec; 148(13):134-8. PubMed ID: 14712541
[No Abstract] [Full Text] [Related]
12. How the research-based industry approaches vaccine development and establishes priorities.
André FE
Dev Biol (Basel); 2002; 110():25-9. PubMed ID: 12477303
[TBL] [Abstract][Full Text] [Related]
13. Hurdles in tissue engineering/regenerative medicine product commercialization: a pilot survey of governmental funding agencies and the financial industry.
Bertram TA; Tentoff E; Johnson PC; Tawil B; Van Dyke M; Hellman KB
Tissue Eng Part A; 2012 Nov; 18(21-22):2187-94. PubMed ID: 22838399
[TBL] [Abstract][Full Text] [Related]
14. An unbalanced portfolio.
Federsel HJ
Drug News Perspect; 2009 Jun; 22(5):287-92. PubMed ID: 19609466
[TBL] [Abstract][Full Text] [Related]
15. Research and development productivity map: visualization of industry status.
Shimura H; Masuda S; Kimura H
J Clin Pharm Ther; 2014 Apr; 39(2):175-80. PubMed ID: 24438433
[TBL] [Abstract][Full Text] [Related]
16. Early assessment of medical technologies to inform product development and market access: a review of methods and applications.
Ijzerman MJ; Steuten LM
Appl Health Econ Health Policy; 2011 Sep; 9(5):331-47. PubMed ID: 21875163
[TBL] [Abstract][Full Text] [Related]
17. Capital disadvantage: America's failing capital investment system.
Porter ME
Harv Bus Rev; 1992; 70(5):65-82. PubMed ID: 10121317
[TBL] [Abstract][Full Text] [Related]
18. Biotech business Down Under.
Beckley C
Nature; 2004 Jun; 429(6991 Suppl):5-9. PubMed ID: 15175704
[No Abstract] [Full Text] [Related]
19. Innovation and the burden of disease: retrospective observational study of new and emerging health technologies reported by the EuroScan Network from 2000 to 2009.
Martino OI; Ward DJ; Packer C; Simpson S; Stevens A
Value Health; 2012; 15(2):376-80. PubMed ID: 22433770
[TBL] [Abstract][Full Text] [Related]
20. Impact of China's Vaccine Incidents on the Operational Efficiency of Biopharmaceutical Companies.
Chai KC; Tao R; Chang KC; Yang Y
Front Public Health; 2020; 8():93. PubMed ID: 32322567
[No Abstract] [Full Text] [Related]
[Next] [New Search]
